Femoral geometric parameters and BMD measurements by DXA in adult patients with different types of osteogenesis imperfecta

Skeletal Radiology

Volumn 42, Issue 2, 2013, Pages 187-194

  Kocijan, Roland ^a   Muschitz, Christian ^a   Fratzl Zelman, Nadja ^b   Haschka, Judith ^a   Dimai, Hans Peter ^c   Trubrich, Angela ^a   Bittighofer, Christina ^a   Resch, Heinrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adults; BMD; Hip structure analysis (HSA); Osteogenesis imperfecta

Indexed keywords

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL AREA; CROSS-SECTIONAL MOMENT OF INERTIA; DIAGNOSTIC IMAGING EQUIPMENT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMORAL STRENGTH INDEX; FEMUR NECK; HEIGHT; HIP RADIOGRAPHY; HIP STRUCTURAL ANALYSIS; HUMAN; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; WEIGHT;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; FEMALE; FEMUR; HUMANS; MALE; MIDDLE AGED; OSTEOGENESIS IMPERFECTA; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84874106867     PISSN: 03642348     EISSN: 14322161     Source Type: Journal    
DOI: 10.1007/s00256-012-1512-4     Document Type: Article

References (41)

1. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. 2000;26:581-9.
2. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002;110:1293-9.
3. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377-85.
4. Gatti D, Viapiana O, Lippolis I, et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res. 2005;20:1323-6.
5. Rousseau JC, Chevrel G, Schott AM, Garnero P. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations. Bone. 2010;46:897-900.
6. Roschger P, Fratzl-Zelman N, Misof BM, Glorieux FH, Klaushofer K, Rauch F. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations. Calcif Tissue Int. 2008;82:263-70.
7. Witecka J, Augusciak-Duma AM, Kruczek A, et al. Two novel COL1A1 mutations in patients with osteogenesis imperfecta (OI) affect the stability of the collagen type I triple-helix. J Appl Genet. 2008;49:283-95.
8. Makareeva E, Cabral WA, Marini JC, Leikin S. Molecular mechanism of α1(I) - osteogenesis imperfecta/Ehlers-Danlos Syndrome. J Biol Chem. 2006;281:6463-70.
9. Chevrel G, Schott AM, Fontanges E, et al. Effects of oral Alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006;21:300-6.
10. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53:1-5.
11. Barnes AM, Carter EM, Cabral WA, et al. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med. 2010;362:521-8.
12. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7:540-57.
13. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-16.
14. Cabral WA, Chang W, Barnes AM, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet. 2007;39:359-65.
15. Paterson CR, McAllion S, Stellman JL. Osteogenesis imperfecta after the menopause. N Engl J Med. 1984;310:1694-6.
16. Wekre LL, Eriksen EF, Falch JA. Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta. Arch Osteoporos. 2011;6:31-8.
17. Miller ME, Hangartner TN. Bone density measurements by computed tomography in osteogenesis imperfecta type I. Osteoporos Int. 1999;9:427-32.
18. Zebaze R, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375:1729-36.
19. Faulkner KG, Wacker WK, Barden HS, et al. Femur strength index predicts hip fracture independent of bone density and hip axis length. Osteoporos Int. 2006;17:593-9.
20. van Londen GJ, Perera S, Vujevich KT, Sereika SM, Bhattacharya R, Greenspan SL. The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial. Bone. 2010;46:655-9.
21. Khoo BC, Wilson SG, Worth GK, et al. A comparative study between corresponding structural geometric variables using 2 commonly implemented hip structural analysis algorithms applied to dual-energy X-ray absorptiometry images. J Clin Densitom. 2009;12:461-7.
22. Martin RB, Burr DB. Non-invasive measurements of long bone cross sectional moment of inertia by photon absorptiometry. J Biomech. 1984;17:195-201.
23. Bonnick SL. HSA: beyond BMD with DXA. Bone. 2007;41:S9-S12.
24. Rauch F, Land C, Cornibert S, Schoenau E, Glorieux FH. High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta. Bone. 2005;37:634-41.
25. Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone. 2006;39:901-6.
26. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005;20:977-86.
27. Ishikawa S, Kumar SJ, Takahashi HE, Homma M. Vertebral body shape as a predictor of spinal deformity in osteogenesis imperfecta. J Bone Joint Surg. 1996;78:212-9.
28. Weber M, Roschger P, Fratzl-Zelman N, et al. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone. 2006;39:616-22.
29. Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone. 2008;42:456-66.
30. Lindahl K, Barnes AM, Fratzl-Zelman N, et al. COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. Hum Mutat. 2011;32:598-609.
31. Bradbury LA, Barlow S, Geoghegan F, et al. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int. 2012;23:285-94.
32. Siu WS, Qin L, Leung KS. pQCT bone strength index may serve as a better predictor than bone mineral density for long bone breaking strength. J Bone Miner Metab. 2003;21:316-22.
33. Kozloff KM, Carden A, Bergwitz C, et al. Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptions to improve whole bone strength. J Bone Miner Res. 2004;19:614-22.
34. Alwis G, Karlsson C, Stenevi-Lundgren S, Rosengren BE, Karlsson MK. Femoral neck bone strength estimated by hip structural analysis (HSA) in Swedish Caucasians aged 6-90 years. Calcif Tissue Int. 2012;90:174-85.
35. Gnudi S, Sitta E, Fiumi N. Bone density and geometry in assessing hip fracture risk in postmenopausal women. Br J Radiol. 2007;80:893-7.
36. Szulc P, Duboeuf F, Schott AM, Dargent-Molina P, Meunier PJ, Delmas PD. Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS study. Osteoporos Int. 2006;17:231-6.
37. Ahlborg HG, Nguyen ND, Nguyen TV, Center JR, Eisman JA. Contribution of hip strength indices to hip fracture risk in elderly men and women. J Bone Miner Res. 2005;20:1820-7.
38. Jamsa T, Jalovaara P, Peng Z, Vaananen K, Tuukkanen J. Comparison of three-point bending test and peripheral quantitative computed tomography analysis in the evaluation of the strength of mouse femur and tibia. Bone. 1998;23:155-61.
39. Melton LJ, Beck TJ, Amin S, et al. Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int. 2005;16:460-7.
40. Prevrhal S, Shepherd JA, Faulkner KG, Gaither KW, Black DM, Lang TF. Comparison of DXA hip structural analysis with volumetric QCT. J Clin Densitom. 2008;11:232-6.
41. LaCroix AZ, Beck TJ, Cauley JA, et al. Hip structural geometry and incidence of hip fracture in postmenopausal women: what does it add to conventional bone mineral density? Osteoporos Int. 2010;21:919-29.